Gene therapy-based approaches to the treatment of cancer: Development of targetable retroviral vectors

Transfusion Science

Volumn 17, Issue 1, 1996, Pages 121-128

  Dougherty, Graeme J ^a   Peters, Carrie E ^a   Dougherty, Shona T ^b   McBride, William H ^c   Chaplin, David J ^d  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; CHIMERIC PROTEIN; COMPLEMENTARY DNA; ENVELOPE PROTEIN; FC RECEPTOR; MONOCLONAL ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; CANCER; CELL TYPE; CONFERENCE PAPER; ENDOTHELIUM CELL; EXPRESSION VECTOR; GENE TARGETING; GENE THERAPY; GENETIC ENGINEERING; LIGAND BINDING; MOLECULAR CLONING; NONHUMAN; RETROVIRUS; VASCULAR ENDOTHELIUM;

EID: 0029887737     PISSN: 09553886     EISSN: None     Source Type: Journal    
DOI: 10.1016/0955-3886(95)00065-8     Document Type: Conference Paper

References (42)

1. Rosenberg SA: The immunotherapy and gene therapy of cancer. J Clin Oncol 1992; 10:180-199.
2. Pardoll DM: Cancer vaccines. Immunol Today 1993; 14:310-316.
3. Tepper RI, Mulé JJ: Experimental and clinical studies of cytokine gene modified tumor cells. Hum Gene Ther 1994; 5:153-164.
4. Anderson WF: Gene therapy of cancer. Hum Gene Ther 1994; 5:1-2.
5. Vile R, Russell SJ: Gene transfer technologies for the gene therapy of cancer. Gene Ther 1994; 1:88-98.
6. Kedar E, Klein E: Cancer immunotherapy: are the results discouraging? Can they be improved? Adv Cancer Res 1992; 59:245-322.
7. Mulligan RC: The basic science of gene therapy. Science 1993; 260:926-932.
8. Hellstrom KE, Hellstrom I: Principles of tumor immunity, in DeVita VT, Hellman S, Rosenberg SA (eds): Biologic Therapy of Cancer. Philadelphia, J.B. Lippincott, 1991; p. 35-52.
9. Miller DA, Rosman GJ: Improved retroviral vectors for gene transfer and expression. Biotechniques 1989; 7:980-988.
10. Miller AD: Retroviral vectors. Curr Top Microbiol Immunol 1992; 158:1-24.
11. Boris-Lawrie KA, Temin HM: Recent advances in retrovirus vector technology. Curr Opinion Genet Devel 1993; 3: 102-109.
12. Jolly D: Viral vector systems for gene therapy. Cancer Gene Ther 1994; 1:51-64.
13. Luciw PA, Leung NJ: Mechanisms of retrovirus replication, in Levy JA (ed.): The Retroviridae. Vol 1. New York, Plenum Press, 1992; pp. 159-298.
14. Miller DA: Retrovirus packaging cells. Hum Gene Ther 1990; 1:5-14.
15. Hunter E, Swanstrom R: Retrovirus envelope glycoproteins. Curr Top Microbiol Immunol 1990; 157:187-253.
16. Russell SJ, Hawkins RE, Winter G: Retroviral vectors displaying functional antibody fragments. Nucl Acids Res 1993; 21:1081-1085.
17. Chu TT, Martinez I, Sheay WC, Dornburg R: Cell targeting with retroviral particles containing antibody-envelope fusion proteins. Gene Ther 1994; 1:292-299.
18. Kasahara N, Dozy AM, Kan YW: Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 1994; 266:1373-1376.
19. Roux P, Jeanteur P, Piechaczyk MA: A versatile and potentially general approach to the targeting of specific cell types by retroviruses: application of the infection of human cells by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine leukemia virus-derived viruses. Proc Natl Acad Sci USA 1989; 86:9079-9083.
20. Etienne-Julan M, Roux P, Carillo S, Jeanteur P, Piechaczyk M: The efficiency of cell targeting by recombinant retroviruses depends upon the nature of the receptor and the composition of the artificial cell-virus linker. J Gen Virol 1992; 73:3251-3255.
21. Gluzman Y: SV40-transformed simian cells support the replication of early SV40 mutants. Cell 1981; 23:175-182.
22. Lynch EM, Sampson LE, Khalil AA, Horsman MR, Chaplin DJ: Cytotoxic effects of tumour necrosis factor-alpha on sarcoma F cells at tumour relevant oxygen tensions. Acta Oncol 1995; 34:423-427.
23. Dougherty GJ, Kay RJ, Humphries RK: Molecular cloning of 114/A10, a cell surface antigen containing highly conserved repeated elements, which is expressed by murine hemopoietic progenitor cells and interleukin-3-dependent cell lines. J Biol Chem 1989; 264:6509-6514.
24. Kay R, Humphries RK: New vectors and procedures for isolating cDNAs encoding cell surface proteins by expression in COS cells. Meth Mol Cell Biol 1991; 2:254-265.
25. Lewis VA, Koch T, Plunter H, Mellman I: A complementary DNA clone for a macrophage lymphocyte Fc receptor. Nature 1986; 324:372-375.
26. Ravetch JV, Luster AD, Weinshank R, Kochan J, Pavlovec A, Portnoy DA, Hulmes J, Pan YE, Unkeless JC: Structural heterogeneity and functional domains of murine immunoglobulin G Fc receptors. Science 1986; 234:718-725.
27. Kinet J: Antibody cell interactions: Fc receptors. Cell 1989; 57:351-354.
28. Hughes P, Thacker JD, Hogge D, Sutherland HJ, Thomas TE, Lansdorp PM, Eaves CJ, Humphries RK: Rectroviral gene transfer to primitive normal and leukemic hematopoietic cells using clinically applicable procedures. J Clin Invest 1992; 89:1817-1824.
29. Howie S, McBride WH: Tumour-specific T helper activity can be abrogated by two distinct suppressor cell mechanisms. Eur J Immunol 1982; 12:671-675.
30. Dvorak HF, Nagy JA, Dvorak AM: Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells 1991; 3:77-85.
31. Denekamp J: Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiology 1993; 66:181-196.
32. Kerbel RS: Inhibition of tumor angiogenesis as a stategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays 1991; 13:31-36.
33. Fidler IJ, Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994; 79:185-188.
34. Burrows FJ, Thorpe PE: Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci USA 1993; 90:8996-9000.
35. Vaupel P, Kallinowski F, Okunieff P: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989; 49:6449-6465.
36. Mueller-Klieser W, Vaupel P, Manz R, Schmidseder R: Intercapillary oxyhaemoglobin saturation of malignant tumors in humans. Int J Radiat Oncol Biol Phys 1981; 7:1397-1404.
37. Vaupel P: Oxygenation of human tumors. Strahlenther Oncol 1990; 166:377-386.
38. Chaplin DJ, Olive PL, Durand RE: Intermittent blood flow in a murine tumor: radiobiological effects. Cancer Res 1987; 47:597-601.
39. Trotter MJ, Chaplin DJ, Durand RE, Olive PL: The use of fluorescent probes to identify regions of transient perfusion in murine tumors. Int J Radiat Oncol Biol Phys 1989; 16:931-934.
40. Chaplin DJ, Hill SA: Temporal heterogeneity in microregional erythrocyte flux in experimental solid tumours. Br J Cancer 1995; 71:1210-1213
41. Andrade SP, Hart IR, Piper PJ: Inhibitors of nitric oxide synthase selectively reduce flow in tumour-associated neovascular. Br J Pharmacol 1992; 107: 1092-1095.
42. Chaplin DJ, Trotter MJ: Chemical modifiers of tumour blood flow, in Vaupel P, Jain K (eds): Tumour Blood Supply and Metabolic Microenvironment. Stuttgart, Gustav Fischer, 1991; pp. 65-85.